High-Energy Stack
SS-31 (50mg) · MOTS-c (40mg) · NAD+ (1000mg)
A particularly strong fit for the GLP-1 fatigue wall — that energy crash people on semaglutide, tirzepatide or retatrutide tend to hit around month 2–3, when rapid fat oxidation outruns mitochondrial capacity. High-Energy Stack restores the cellular machinery so weight loss can continue without the fatigue tax. Most chronic fatigue, metabolic inflexibility and slow recovery trace back to one root cause: mitochondria that can't produce enough ATP. The stack addresses this at three levels — SS-31 repairs cardiolipin membrane structure, MOTS-c retrains metabolic signaling to build new mitochondria, and NAD+ restores the redox currency both processes consume. Typically run as an 8–12 week cycle.
Dosage
Start SS-31 5mg 3× weekly · MOTS-c 5mg 2× weekly · NAD+ 50mg 2× weekly; after 1 week move MOTS-c to 3× weekly and NAD+ to 100mg 2–3× weekly (vial sizes above are multi-dose supplies, not single doses)
Key Features
- 3 core mitochondrial compounds
- Repair · Signal · Fuel
- GLP-1 fatigue protocol
- 12-week cycle
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Cell Metabolism - ScienceDirect
Clinical Research
Mitochondrial-targeted interventions combining NAD+ precursors with metabolic activators show synergistic effects on cellular energy production and metabolic health.
Read full studyAdditional Research
Source: Martens et al., Nature Communications (2018)
In a 6-week placebo-controlled trial in healthy middle-aged and older adults, oral NAD+ precursor supplementation was well tolerated and significantly elevated whole-blood NAD+ — direct human evidence that NAD+ pools can be restored.
Read full study